Core Insights - Parkman Healthcare Partners disclosed a new position in Masimo Corporation by acquiring 200,000 shares worth approximately $26.01 million at the end of the fourth quarter [1][2] Company Overview - Masimo Corporation is a leading provider of advanced noninvasive monitoring technologies and hospital automation solutions, with a market capitalization of $9.4 billion and revenue of $1.5 billion [4][6] - The company reported a net income of -$151.5 million for the trailing twelve months [4] - Masimo's stock price was $175.49 as of the last trading day [4] Business Model - Masimo generates revenue primarily through the sale of proprietary medical devices and software platforms to healthcare providers and OEM partners, serving a wide range of clients including hospitals and emergency medical services [9] Recent Developments - Shares of Masimo have surged 35% this year, largely due to the announcement of an acquisition deal valued at approximately $9.9 billion, with a cash offer of $180 per share [8] - The acquisition is expected to close in the second half of the year, highlighting the strategic value of Masimo's technology and hospital relationships [11] Investment Implications - The new stake by Parkman Healthcare Partners represents 2.48% of its $1.05 billion in reportable U.S. equity assets as of December 31, 2025, indicating a strategic focus on companies with strong intellectual property and durable demand [8][11]

Core Thesis - A bullish thesis on Papa John's International, Inc. (PZZA) has emerged, particularly focusing on a potential takeover offer from Apollo at $64 per share, which represents a significant premium over the current trading price [2][4]. Stock Performance and Valuation - As of October 14th, PZZA's share was trading at $48.68, with trailing and forward P/E ratios of 21.02 and 20.12 respectively [1]. - The stock has remained flat over the past year despite a strong bull market, indicating market caution regarding the unconfirmed takeover bid [3]. Takeover Offer Details - Apollo's reported takeover offer of $64 per share is approximately 30–35% above the current trading range of $45–$50, suggesting a strong likelihood of acceptance after due diligence [2]. - The offer represents a ~50% premium over PZZA's pre-rumor stock price, enhancing the attractiveness of the investment opportunity [2]. Shareholder Dynamics - The lack of a controlling shareholder and significant institutional ownership from firms like BlackRock and Vanguard may facilitate Apollo's bid approval [3]. - Activist investor Irth Capital, holding nearly 5% of shares and previously aligned with Apollo, is likely to support the bid, adding credibility to the takeover scenario [3]. Potential Upside and Risks - If the $64 offer is confirmed and accepted, investors could see gains of 30–35% from the current share price, with additional upside possible if the offer increases [4]. - The downside risk is estimated at around 15% if the offer is rejected, potentially bringing shares back to the $42–$43 range [4]. - A conservative investment strategy involves buying common shares for a 2:1 reward-to-risk ratio, while options like $50 strike calls expiring January 16, 2026, offer leveraged exposure with higher risk [4]. Previous Coverage and Long-term Outlook - Previous bullish coverage highlighted potential buyout scenarios and operational improvements, with PZZA's stock appreciating approximately 8.68% since that coverage [5]. - The current thesis aligns with earlier insights, emphasizing the potential for near-term upside driven by the takeover offer [5].